Compare TX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TX | KRYS |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 9.6B |
| IPO Year | 2006 | 2017 |
| Metric | TX | KRYS |
|---|---|---|
| Price | $57.75 | $348.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $37.70 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 489.2K | 200.3K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 3.62 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $9.60 | $38.74 |
| Revenue Next Year | $6.66 | $32.53 |
| P/E Ratio | ★ $20.15 | $96.16 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $33.01 | $145.46 |
| 52 Week High | $58.73 | $382.54 |
| Indicator | TX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 48.23 |
| Support Level | $53.41 | $289.36 |
| Resistance Level | $58.24 | $382.33 |
| Average True Range (ATR) | 1.56 | 11.24 |
| MACD | -0.03 | -0.73 |
| Stochastic Oscillator | 68.96 | 28.36 |
Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.